The board of Therapeutic Proteins International (TPI) today announced the appointment of Michael W. Washabaugh, Ph.D. as its new chief scientific officer.
Dr. Washabaugh has more than 20 years of experience in therapeutic protein and vaccine development. Prior to joining TPI, he assumed a senior leadership R&D role at MedImmune, a subsidiary of AstraZeneca, primarily responsible for preclinical and late stage clinical development of vaccine and biological candidates. Previous to this role, he was the head of Vaccine and Biologics Analytical Sciences at Merck, leading or supporting numerous viral and recombinant protein product approvals. Prior to his leadership roles in industry, Dr. Washabaugh was on the faculty of the departments of biochemistry and environmental health sciences at Johns Hopkins University, School of Hygiene and Public Health.
“Mike has a proven track record of leading research teams and delivering a broad and diverse pipeline of biologics and vaccines,” said Dr. Peter Moesta, chief executive officer, TPI. “With his extensive analytical knowledge of therapeutic protein and vaccine development, I am confident that under Mike’s leadership, TPI will be able to deliver high quality, affordable alternatives to branded biologics and make a difference for patients.”
“With his extensive analytical knowledge of therapeutic protein and vaccine development, I am confident that under Mike’s leadership, TPI will be able to deliver high quality, affordable alternatives to branded biologics and make a difference for patients.”
Dr. Washabaugh completed his bachelor’s degree, with honors, at the University of Michigan. He received his doctorate in biochemistry from John Hopkins University, followed by post-doctoral studies in biochemistry at Brandeis University. Throughout his career, Dr. Washabaugh has become a widely published author and speaker in the fields of chemistry, biochemistry, immunology, virology and the development of biopharmaceuticals.
“It has been my life-long commitment to bring innovative medicines and vaccines to market that improve the lives of patients around the world,” said Michael Washabaugh, Ph.D. “I am honored to have the opportunity to continue to carry on this type of work at TPI, alongside a group of highly talented scientists and engineers.”
About Adello Biologics, LLC
Adello is a privately held, U.S.-based biotechnology company that leads with science to accelerate development and drive manufacturing efficiency. The company’s aim is to provide high-quality, affordable biosimilars to patients worldwide. Headquartered in Piscataway, NJ and driven by a team of highly skilled industry veterans, Adello is advancing a strategic pipeline of proteins and complex monoclonal antibodies with lead candidates in oncology and immunology. For more information, visit Adellobio.com.
Learn more about biosimilars: adellobio.com/biosimilars
For additional information:
Adello Biologics, LLC
Source: Adello Biologics, LLC